NCT04961333 (COVID-19) is a NA clinical trial of Multidisciplinary Rehabilitation in Long COVID-19, sponsored by Danderyd Hospital.

Who is sponsoring NCT04961333?

NCT04961333 is sponsored by Danderyd Hospital.

What drugs are being tested in NCT04961333?

Interventions in NCT04961333: Multidisciplinary Rehabilitation.

What condition does NCT04961333 study?

NCT04961333 studies Long COVID-19.

Is NCT04961333 still recruiting?

NCT04961333 is currently status unknown. Last updated 14 July 2021.

Last reviewed 2021-07-14 · How we verify

NCT04961333: COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome

Status unknown NA Last updated 14 July 2021

What this trial tests

NA trial testing Multidisciplinary Rehabilitation in Long COVID-19 in 200 participants. Status unknown.

Timeline

23 April 2021

Primary endpoint
31 December 2021

31 December 2022

Quick facts

Lead sponsor	Danderyd Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	200
Start date	23 April 2021
Primary completion	31 December 2021
Estimated completion	31 December 2022
Sites	1 location across Sweden

Drugs / interventions tested

Multidisciplinary Rehabilitation

Conditions studied

Long COVID-19 — all drugs for Long COVID-19 →

Sponsor

Danderyd Hospital

Who can join

Adults 18 to 67, any sex, with Long COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Internet-based multidisciplinary interventions will be offered to participants suffering from longterm COVID-19 syndrome. Data will be collected by internet platform at Karolinska Institutet (BASS) before, after rehabilitation and at follow-up after 6 months. Both self-scored questionnaires and physical tests performed at home will be collected to understand the symptomatology, functioning and activity level. Rehabilitation during 8 weeks period will be given in groups as face-to-group, pre-recorded film sessions and by individual approach, the participants will use ExorLive app for physical activity.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Pain Burden in Post-COVID-19 Syndrome following Mild COVID-19 Infection.
Bileviciute-Ljungar I, Norrefalk JR, Borg K. · · 2022 · cited 39× · PMID 35160223 · DOI 10.3390/jcm11030771
Self-scored impairments in functioning and disability in post-COVID syndrome following mild COVID-19 infection.
Norrefalk JR, Borg K, Bileviciute-Ljungar I. · · 2021 · cited 20× · PMID 34643243 · DOI 10.2340/jrm.v53.188
Improved Functioning and Activity According to the International Classification of Functioning and Disability after Multidisciplinary Telerehabilitation for Post-COVID-19 Condition-A Randomized Control Study.
Bileviciute-Ljungar I, Norrefalk JR, Borg K. · · 2024 · cited 6× · PMID 38398284 · DOI 10.3390/jcm13040970
A First Randomized Eight-Week Multidisciplinary Telerehabilitation Study for the Post-COVID-19 Condition: Improvements in Health- and Pain-Related Parameters.
Bileviciute-Ljungar I, Apelman A, Braconier L, Östhols S, et al · · 2025 · cited 2× · PMID 39860492 · DOI 10.3390/jcm14020486

Verify or expand the search:

Other trials of Multidisciplinary Rehabilitation

Trials testing the same drug.

NCT05230927 — Cognitive Impairment, Frailty and Rehabilitative Outcome in Older Patients Affected by Cardiorespiratory Disease · completed

Other recruiting trials for Long COVID-19

Currently open trials in the same condition.

NCT06960928 — Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 · Phase 3 · recruiting
NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
NCT06404099 — RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) · Phase 2 · active not recruiting
NCT06404112 — RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) · Phase 2 · active not recruiting
NCT07005947 — Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project · active not recruiting

Other Danderyd Hospital trials

Trials by the same sponsor.

NCT06275503 — STROKESTOP III - Optimized Method for Atrial Fibrillation Screening · NA · recruiting
NCT06346145 — Impact of Bariatric Surgery on Heart Disease Compared to Standard Care · NA · not yet recruiting
NCT07476703 — Expanded Studies on the SCAPIS Stockholm Reexamination Cohort · recruiting
NCT05359367 — A Novel Approach to Enhance True Recovery After Stroke · terminated
NCT06734247 — Arterial Stiffness for Improved Prediction of Coronary Artery Disease by Coronary CT Angiography · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04961333 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Danderyd Hospital
Last refreshed: 14 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04961333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing